Abivax S.A.
AAVXF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.16 | -0.08 | 0.09 | -0.05 |
| FCF Yield | -17.02% | -15.41% | -9.62% | -12.40% |
| EV / EBITDA | -4.59 | -4.38 | -9.76 | -4.06 |
| Quality | ||||
| ROIC | -166.92% | -59.54% | -32.97% | -33.70% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 83.16% |
| Cash Conversion Ratio | 0.66 | 0.73 | 1.04 | 0.73 |
| Growth | ||||
| Revenue 3-Year CAGR | – | 1,197.35% | 249.81% | 123.07% |
| Free Cash Flow Growth | 3.78% | 18.86% | -22.63% | -140.20% |
| Safety | ||||
| Net Debt / EBITDA | -0.40 | 0.51 | 1.36 | 2.18 |
| Interest Coverage | -13.37 | -84.15 | -10.14 | -15.82 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 351.89 | 217.03 | -3,015.33 |